ANTITUMOR ACTIVITY OF <i>ACONITUM SOONGARICUM (RANUNCULACEAE) </i>TINCTURE IN MODELS OF TRANSPLANTED LEUKEMIAS AND SOLID TUMORS
Spectrum of antitumor activity of standardised tincture from tubers of Aconitum soongaricum Stapf in comparison with cyclophosphamide was studied in four models of transplanted tumors in 180 female mice. A. soongaricum tincture administered perorally at a maximal tolerable dose (MTD) 16.3 ml/kg of body weight in dilution by the distilled water 1:10 daily within 5 days and also at a dose of 25 % from MTD daily within 30 days or 12.5 % from MTD daily till the end of a life significantly inhibited growth of the tumors: increased average life span of mice with lymphocytic leukemia P388 and lymphoid leukemia L1210 by 36 and 33 %, accordingly; reduced tumor average volume with the 45 % maximum tumor growth inhibition in mice with epidermoid Lewis lung carcinoma; reduced tumor average volume with the 47 % maximum tumor growth inhibition in mice with melanoma В16 and increased average life span of the animals by 35 %. In spite of the fact that the anti-tumor effects of A. soongaricum tincture was weaker compared with cyclophosphamide administered intramuscularly at a single dose of 150 or 200 mg/kg of body weight A. soongaricum and its separate alkaloids are perspective for creation of plant origin antitumor drug of new group.